Don’t Let Recent momentum Confuse Your Outlook on Agios Pharmaceuticals Inc. [AGIO]

Agios Pharmaceuticals Inc. [AGIO] stock is down -16.01 while the S&P 500 has risen 0.28% on Tuesday, 12/08/20. While at the time of this article, AGIO ATR is sitting at 2.47, with the beta value at 1.82. This stock’s volatility for the past week remained at 5.15%, while it was 4.64% for the past 30-day period. AGIO has fallen -$7.01 from the previous closing price of $43.79 on volume of 2.75 million shares.

On 7, December 2020, Agios Announces Updated Data from Phase 1 Study of Mitapivat, First-in-Class PKR Activator, in Sickle Cell Disease. According to news published on Yahoo Finance, – Treatment with Mitapivat Induced Hemoglobin Increase of ≥1.0 g/dL in 6 of 11 (55%) Efficacy Evaluable Patients, Decreased Markers of Hemolysis, Reduced 2,3-DPG and Increased ATP –.

Analyst Birdseye View:

The most recent analyst activity for Agios Pharmaceuticals Inc. [NASDAQ:AGIO] stock was on March 04, 2020, when it was Initiated with an Equal weight rating from Barclays, which also raised its 12-month price target on the stock to $50. Before that, on October 22, 2020, Barclays Recapitulated an Overweight rating and elevated its amount target to $46. On November 26, 2019, Cantor Fitzgerald Initiated an Overweight rating and boosted its price target on this stock to $64. On September 23, 2019, Guggenheim Upgrade a Buy rating and increased its price target to $55. On May 23, 2019, Goldman Resumed a Neutral rating and increased its price target to $55. On February 15, 2019, SVB Leerink Upgrade an Outperform rating and boosted its amount on this stock to $80. On September 25, 2018, Leerink Partners Initiated a Mkt perform rating. On May 23, 2018, Citigroup Initiated a Buy rating and improved its amount target to $117.

In the past 52 weeks of trading, this stock has oscillated between a low of $27.77 and a peak of $56.74. Right now, according to Wall Street analyst the average 12-month amount target is $63.33. At the most recent market close, shares of Agios Pharmaceuticals Inc. [NASDAQ:AGIO] were valued at $36.78. According to the average price forecast, investors can expect a potential return of 4.73%.

FUNDAMENTAL ANALYSIS

Agios Pharmaceuticals Inc. [NASDAQ:AGIO] most recently reported quarterly sales of 34.71 billion, which represented growth of 33.50%. This publicly-traded organization’s revenue is $219,985 per employee, while its income is -$767,672 per employee. This company’s Gross Margin is currently 98.90%, its Pretax Margin is -348.97, and its Net Margin is -348.97. Continuing to look at profitability, this corporation’s Return on Assets, Equity, Whole Principal & invested Principal is sitting at -47.05, -61.97, -59.14 and -57.36 respectively.

If looking now at the Principal structure of this organization, it shows its whole liability to the whole Principal at 15.07 and the whole liability to whole assets at 12.76. It shows enduring liability to the whole principal at 14.15 and enduring liability to assets at 0.12 while looking for an extended time period.

Readers are usually of view to make a close observation to the indicators that support and make resistance before moving to any particular stock. As of now, the company’s stock is sitting at 35.60 points at 1st support level, the second support level is making up to 34.42. But as of 1st resistance point, this stock is sitting at 38.73 and at 40.68 for 2nd resistance point.

Agios Pharmaceuticals Inc. [AGIO] reported its earnings at -$1.43 per share in the fiscal quarter closing of 9/29/2020. The Analysts for Wall Street were expecting to report its earnings at -$1.38/share signifying the difference of -0.05 and -3.60% surprise value. Comparing the previous quarter ending of 6/29/2020, the stated earnings were -$1.31 calling estimates for -$1.37/share with the difference of 0.06 depicting the surprise of 4.40%.

Important Ratio’s To Watch

Meanwhile, turning our focus to liquidity, the Current Ratio for Agios Pharmaceuticals Inc. [NASDAQ:AGIO] is 9.60. Likewise, the Quick ratio is also the same, showing Cash ratio at 6.08. Now if looking for a valuation of this stock’s amount to sales ratio it’s 24.30 and it’s amount to book ratio is 5.10.

Insider Stories

The most recent insider trade was by Alenson Carman, Principal Accounting Officer, and it was the sale of 250.0 shares on Sep 02. Bowden Christopher, the Chief Medical Officer, completed a sale of 3583.0 shares on May 20. On Mar 02, Alenson Carman, Principal Accounting Officer, completed a sale of 345.0 shares.